Plenary Sessions
- Innovations in Liver Disease Therapy: Present and Future
- Public Health Interventions in Liver Diseases
- New vaccine approaches for Liver Diseases
Global Hepatitis Summit 2023 Debrief
Clinical Science Sessions
- Difficult-to-treat HCV patients
- New strategies with approved HBV treatments
- New HBV drug clinical developments
- New HDV therapies
- Long-term outcomes of treated patients with viral hepatitis
- Viral hepatitis and transplantation
- Hepatitis vaccines and vaccination
- Impact of COVID-19 on liver disease management
- NASH therapeutic developments
- Hepatocellular carcinoma therapeutic developments
- New biomarkers in liver diseases
- Artificial intelligence in liver disease management
Public Health Sessions
- Epidemiology of viral hepatitis in resource-limited countries
- Viral hepatitis elimination
- Simplified approaches for screening and diagnosis of viral hepatitis
- Reaching vulnerable populations for viral hepatitis elimination
- Viral hepatitis elimination: the patient’s perspective
- NOHep Village
Basic Science Sessions
- HCV and flavivirus virology
- HCV immunology
- HBV/HDV virology
- HBV/HDV immunology
- HBV/HDV treatment targets
- New models for liver disease pathogenesis studies
- NASH targets for new therapies
- Hepatocellular carcinoma targets for new therapies
- HAV/HEV virology
- Liver inflammation and fibrogenesis
Joint Institutional Partner
and Scientific Society
Sessions
(French and International)
- Special topic symposia
- Co-Located programs
Poster sessions
- Clinical Science
- Public Health
- Basic Science
Industry Supported Programs
- Breakfast, lunch and evening symposia
- Meet the expert sessions
- Panel discussions
- Advisory board meeting
- Investigators meetings
- Affiliate meeting space
